Ola Lindén

1 – 10 of 38

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/onk-oli?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
2
3
4
next »

2018
Mark Targeted Alpha Therapy, an Emerging Class of Cancer Agents : A Review
Parker, Christopher ; Lewington, Valerie ; Shore, Neal ; Kratochwil, Clemens ; Levy, Moshe ; Lindén, Ola ^LU ; Noordzij, Walter ; Park, Jae and Saad, Fred (2018) In JAMA Oncology 4(12). p.1765-1772
- Contribution to journal › Scientific review
2016
Mark Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
SZENTKIRALYI SZEKELY, ERZSÉBET ^LU ; Lindén, Ola ^LU ; Peterson, Stefan ^LU and Jerkeman, Mats ^LU (2016) In European Journal of Haematology 97(4). p.393-398
- Contribution to journal › Article
2015
Mark Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women - a Swedish Lymphoma Registry study.
Junlén, H R ; Peterson, Stefan ^LU ; Kimby, E ; Lockmer, S ; Lindén, Ola ^LU ; Nilsson-Ehle, H ; Erlanson, M ; Hagberg, H ; Rådlund, A and Hagberg, Oskar ^LU , et al. (2015) In Leukemia 29(3). p.668-676
- Contribution to journal › Article
Mark Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
Jerkeman, Mats ^LU and Lindén, Ola ^LU (2015) In European Journal of Haematology
- Contribution to journal › Article
Mark Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.
Palmason, Robert ^LU ; Lindén, Ola ^LU and Richter, Johan ^LU (2015) In BMC Hematology 15. p.10-10
- Contribution to journal › Article
2013
Mark 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial.
Scholz, Christian W ; Pinto, Antonello ; Linkesch, Werner ; Lindén, Ola ^LU ; Viardot, Andreas ; Keller, Ulrich ; Hess, Georg ; Lastoria, Secondo ; Lerch, Kristina and Frigeri, Ferdinando , et al. (2013) In Journal of Clinical Oncology 31(3). p.308-313
- Contribution to journal › Article
2011
Mark Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.
Sjögreen Gleisner, Katarina ^LU ; Dewaraja, Y K ; Chiesa, C ; Tennvall, Jan ^LU ; Lindén, Ola ^LU ; Strand, Sven-Erik ^LU and Ljungberg, Michael ^LU (2011) In Quarterly Journal of Nuclear Medicine and Molecular Imaging 55(2). p.126-154
- Contribution to journal › Article
Mark Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Ageberg, Malin ^LU ; Fjordén, Karin ^LU ; Lindén, Ola ^LU ; Linderoth, Johan ^LU ; Jerkeman, Mats ^LU and Drott, Kristina ^LU (2011) In Experimental Cell Research 317. p.1179-1191
- Contribution to journal › Article
Mark T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
Wahlin, Bjorn Engelbrekt ; Sundstrom, Christer ; Holte, Harald ; Hagberg, Hans ; Erlanson, Martin ; Nilsson-Ehle, Herman ; Lindén, Ola ^LU ; Nordstrom, Marie ; Ostenstad, Bjorn and Geisler, Christian H. , et al. (2011) In Clinical Cancer Research 17(12). p.4136-4144
- Contribution to journal › Article
2010
Mark 90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.
Minarik, David ^LU ; Sjögreen Gleisner, Katarina ^LU ; Lindén, Ola ^LU ; Wingårdh, Karin ^LU ; Tennvall, Jan ^LU ; Strand, Sven-Erik ^LU and Ljungberg, Michael ^LU (2010) In Journal of Nuclear Medicine 51(12). p.1974-1978
- Contribution to journal › Article

« previous
1
2
3
4
next »